Michael Diaz, MD, president and managing physician, Florida Cancer Specialists & Research Institute, previews the Tampa meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), cohosted by Florida Cancer Specialists & Research Institute.
The latest advances in personalized care and precision medicine will be addressed at the upcoming in-person Institute for Value-Based Medicine® (IVBM) meeting in Tampa, Florida, said Michael Diaz, MD, president and managing physician, Florida Cancer Specialists & Research Institute.
Transcript
Can you discuss the theme of the upcoming Tampa IVBM Meeting?
We're so excited to be able to hold that here in Tampa, Florida, but more specifically, closely to where I live in practice in Tampa. We're going to be highlighting several different components that I think are important for everybody to know.
We want everybody to know and understand the advances that we're making with personalized care and personalized medicine, hat does that mean for the patients, how is that accomplished with new advanced testing techniques, and then how that's achieved with new medications. And I think one of the things that we will continue to see, especially as time evolves, the more personalized we can make the medicine, the more effective it will be for the patients, the better outcomes we're going to have. It's going to be a win-win.
Why are in-person meetings important for physicians as we emerge from the pandemic?
That's a very interesting question. In-person meetings are irreplaceable. It allows us to have quick access to some of the most amazing colleagues we will ever have. We can curbside people, we can ask questions, we can stimulate thought, we get ideas—there's a lot of synergy that results very quickly after having an in-person meeting that just cannot be duplicated with virtual meetings.
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Mitigating Barriers to Cell and Gene Therapy Access
February 14th 2025Cell and gene therapies can be life-changing for patients with certain conditions, but the process of receiving them poses barriers for patients and caregivers that require multistakeholder solutions, according to a white paper from the National Pharmaceutical Council.
Read More